Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
In children 4 to 7 years of age, to determine if treatment with 1 hour per day 6 days per week of watching dichoptic movies/shows wearing the Luminopia headset is non-inferior to treatment with 2 hours of patching per day 7 days per week with respect to change in amblyopic eye distance VA from randomization to 26 weeks.
Full description
Participants eligible for the study will be randomly allocated (1:1) to receive either dichoptic treatment while wearing the Luminopia headset or patching treatment of the fellow eye for amblyopia with clinical assessments at 13, and 26-weeks post-randomization.
At the 26-week primary outcome visit, participants who were randomly assigned to receive patching treatment with an IOD of 1 logMAR line or more, will be offered Luminopia dichoptic therapy and if they accept, followed forward with visits at 39- and 52-weeks post-randomization.
The study will end for all other participants.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
At the time of enrollment, individuals must meet all the following inclusion criteria to be eligible to participate in the study.
Age 4 to 7 years.
Visual acuity, measured in each eye without cycloplegia in current refractive correction (if applicable) using the ATS-HOTV VA protocol on a study-approved device displaying single surrounded optotypes, as follows:
VA in the amblyopic eye 20/40 to 20/200 inclusive.
Age-normal VA in the fellow eye:44,45
• 4 years: 20/40 or better; 5-6 years: 20/32 or better; 7 years: 20/25 or better
Interocular difference ≥ 3 logMAR lines (i.e., amblyopic eye VA at least 3 logMAR lines worse than fellow eye VA).
Amblyopia associated with strabismus, anisometropia, or both (previously treated or untreated).
Criteria for strabismic amblyopia: At least one of the following must be met:
Criteria for anisometropia: At least one of the following criteria must be met:
Criteria for combined-mechanism: Both of the following criteria must be met:
No more than 2 weeks (cumulative) of prior dichoptic treatment.
No treatment with cycloplegic eyedrops (e.g., atropine) in the past 2 weeks; other treatments allowed up to enrollment but then must be discontinued.
Refractive correction is required (single vision lenses or contact lenses) for any of the following refractive errors based on a cycloplegic refraction completed within the last 7 months:
NOTE: Monocular or binocular contact lens wear is allowed provided the contact lenses meet the refractive error correction requirements below. For each child, all testing must be performed using the same form of optical correction (i.e., no changing between contacts and spectacles).
Spectacles/contact lens correction prescribing instructions referenced to the cycloplegic refraction completed within the last 7 months:
Spectacles/contact lens correction (with or without other treatment such as patching) meeting the above criteria must be worn:
For at least 18 weeks OR until VA stability is documented (defined as <0.1 logMAR change by the same testing method measured on 2 consecutive exams at least 9 weeks apart).
For determining VA stability (non-improvement):
Participant is willing to wear the Luminopia headset.
Participant is willing to continue full-time spectacles/contact lens wear (if needed).
Participant is willing to accept assignment to either dichoptic shows (view 1 hour per day 6 days per week) OR part-time patching (2 hours per day 7 days per week) for 26 weeks.
Interpupillary distance of 52mm to 72mm inclusive.
Investigator is willing to prescribe Luminopia or patching per protocol.
Parent understands the protocol and is willing to accept randomization.
Parent has phone (or access to phone) and is willing to be contacted by JAEB Center.
Relocation outside area of active PEDIG site within the next 52 weeks is not anticipated.
Individuals meeting any of the following criteria will be excluded from study participation.
Primary purpose
Allocation
Interventional model
Masking
238 participants in 2 patient groups
Loading...
Central trial contact
Raymond T Kraker, MSPH; Brooke P Fimbel
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal